48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.

Alfonso Cabello ÚbedaJuan Carlos López Bernardo de QuirósLuz Martín CarboneroJesús SanzJorge VergasÁlvaro MenaMiguel TorralbaMarta Hernández SeguradoAdriana PintoFrancisco TejerinaEsmeralda PalmierÁngela GutiérrezPilar VázquezFederico PulidoMiguel Górgolas

Published in: PloS one (2022)

In a real-life multicenter cohort of ART-naïve PLWH, treatment initiation with DTG + 3TC showed high effectiveness and favorable safety results, comparable to those of randomized clinical trials, without treatment-emergent resistance being observed through week 48. Starting treatment before receiving the results of baseline drug resistance testing did not have an impact on the regimen's effectiveness.

Keyphrases

randomized controlled trial
systematic review
hiv infected patients
human immunodeficiency virus
combination therapy
antiretroviral therapy
hiv aids
hepatitis c virus
hiv positive